Cytokine and Visual Outcome Variations in Eyes Receiving Ranibizumab (COVERT)

Cytokine and Visual Outcome Variations in Eyes Receiving a Variable Dosing Ranibizumab Treatment: The COVERT Study

Objective: To determine the association between baseline aqueous cytokine levels and treatment intervals for patients under a variable dosing regimen with intravitreal ranibizumab in patients with neovascular age-related macular degeneration (nAMD), macular edema secondary to retinal vein occlusion (RVO) and diabetic macular edema (DME).

Methods: A prospective, single-centre study will be performed containing 3 sub-studies according to each study population: nAMD, macular edema secondary to RVO and DME. Inclusion criteria are: patients followed at St. Michael's Hospital with the diagnosis of nAMD, macular edema secondary to RVO or DME. Patients will be excluded if visual acuity is worse than counting fingers, with macular pathologies causing any structural changes to the retina, have received anti-VEGF injections or photocoagulation therapy 6 months prior to study, intraocular surgery 3 months prior to study, any history of vitreoretinal surgery or ocular inflammation in the study eye, use of systemic or topical anti-inflammatory or steroids, patients on dialysis for renal failure, allergy to the study drug or fluorescein, <18 years old, women who are pregnant. All patients will be treated with ranibizumab intravitreal injections on a variable dosing regimen: Patients with DME will be examined monthly and receive mandatory injection for the first three months (baseline, weeks 4 and 8). Afterwards, they will continue to be seen monthly and the need for new injections will be decided upon the clinical findings at each visit. An anterior chamber (AC) tap will be done if an injection is required at the visit. Patients with nAMD and RVO will be examined monthly and receive mandatory injection for the first three months. From weeks 12 until 72 (month 18), the visits will be scheduled at increasing 2-weeks intervals based on the stability of the ocular condition and response to treatment. At each visit, an injection and AC tap will be performed. The maximum interval in between injections is 12 weeks. If the disease becomes unstable, the interval in between injections is shortened and, once it stabilizes, the treatment frequency is extended again. In all patients, baseline aqueous humour specimens will be obtained prior to the first ranibizumab intravitreal injection and follow-up samples will be taken immediately prior to subsequent injections based on the treatment regimens for cytokine analysis in the end of the follow-up.

Study Overview

• Status: Recruiting
• Conditions: Diabetic Macular Edema; Macular Edema; Retinal Vein Occlusion; Age Related Macular Degeneration
• Intervention / Treatment: Drug: Intravitreal ranibizumab

• Study Type: Interventional
• Enrollment (Anticipated): 168
• Phase: Phase 4

Contacts and Locations

Study Locations

• Canada
  • Toronto, Canada
    • Recruiting
    • Sunnybrook Health Sciences Centre
  • Ontario
    • Toronto, Ontario, Canada, M5C 2T2
      • Recruiting
      • Department of Ophthalmology, St Michael's Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Diagnosis of active choroidal neovascularization secondary to AMD in the study eye
• Diagnosis of macular edema secondary to RVO: central macular thickness >310μm due to intraretinal or subretinal edema in the study eye as measured on OCT
• Diagnosis of DME with central macular thickness >310μm in the study eye as measured on OCT in patients with diabetes mellitus types 1 or 2

Exclusion Criteria:

• Previous intravitreal drug injections in either eye within 6 months prior to study enrollment
• Visual acuity worse than counting fingers
• Patients with other macular pathologies causing structural changes to the retina
• Patients with large submacular hemorrhages or extensive fibrosis occupying the majority (>50%) of the lesion
• Intraocular surgery in the study eye 3 months prior to study enrollment
• Previous vitreoretinal surgery in the study eye
• Previous photodynamic or macular photocoagulation therapy within the past 6 months in the study eye for patients with AMD
• Previous photocoagulation therapy within 6 months in the study eye or anticipated need for during the course of the study for patients with RVO
• Presence of active proliferative diabetic retinopathy or patients who have had pan-retinal photocoagulation within 6 months or patients where the need to pan-retinal photocoagulation is anticipated during the course of the study for patients with DME
• History of intraocular inflammation in the study eye
• Patients on systemic or topical anti-inflammatory or steroids medications
• Patients receiving dialysis for renal failure
• Known allergy to the study drug or fluorescein
• Patients who are pregnant
• Unwilling or unable to follow or comply with all study related procedures or to sign consent form

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: NA
• Interventional Model: SINGLE_GROUP
• Masking: NONE

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
OTHER: AMD/RVO/DME; Patients presenting to St. Michael's Hospital retina clinic with neovascular age related macular degeneration, macular edema secondary to RVO and diabetic macular edema treated with intravitreal ranibizumab in a variable dosing regimen.	Drug: Intravitreal ranibizumab; Patients will be treated with intravitreal ranibizumab and have their aqueous humor obtained for cytokine analysis at every visit that an intravitreal injection is done

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Association between aqueous cytokine levels and optimal treatment interval	Optimal treatment intervals based on aqueous cytokine levels	18 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Average number of injections needed	Average number of injections needed in a variable dosing regimen protocol over an 18 months period.	18 months
Individualized relationships between aqueous cytokines and treatment response	Aqueous cytokine curves for each patient over based on the relationship between cytokine levels and treatment response	18 months
Relationship between cytokine threshold level and visual/anatomic outcomes	Cytokine threshold level below which visual and anatomic outcomes are greatest	18 months
Snellen visual acuity change	Snellen Best Corrected Visual Acuity (BCVA) change at months 1 and 2, and at the visits scheduled for each injection throughout an 18 months period	months 1, 2 and at every visit scheduled for each injection throughout 18 months period
ETDRS visual acuity change	Visual acuity (ETDRS) change at month 2 (at the third injection), at the visits closest to injection of months 6, 12 and 18.	month 2, visits closest to injection of months 6, 12 and 18
Optical coherence tomography (OCT) change	Anatomic OCT change (Macular Volume, Central Macular Thickness) at months 1 and 2, and at the visits scheduled for each injection throughout an 18 months period.	months 1 and 2, and at the visits scheduled for each injection throughout an 18 months period.

Collaborators and Investigators

• Sponsor: Unity Health Toronto

Study record dates

Study Major Dates

• Study Start (ACTUAL): February 28, 2017
• Primary Completion (ANTICIPATED): February 28, 2024
• Study Completion (ANTICIPATED): February 28, 2024

Study Registration Dates

• First Submitted: February 1, 2017
• First Submitted That Met QC Criteria: February 13, 2017
• First Posted (ACTUAL): February 17, 2017

Study Record Updates

• Last Update Posted (ACTUAL): April 28, 2021
• Last Update Submitted That Met QC Criteria: April 27, 2021
• Last Verified: April 1, 2021

More Information

Terms related to this study

• Keywords: diabetic macular edema; age related macular degeneration; ranibizumab; retinal vein occlusion; aqueous cytokine
• Additional Relevant MeSH Terms: Cardiovascular Diseases; Vascular Diseases; Eye Diseases; Retinal Degeneration; Retinal Diseases; Embolism and Thrombosis; Venous Thrombosis; Thrombosis; Macular Degeneration; Macular Edema; Retinal Vein Occlusion; Edema; Physiological Effects of Drugs; Antineoplastic Agents; Angiogenesis Inhibitors; Angiogenesis Modulating Agents; Growth Substances; Growth Inhibitors; Ranibizumab
• Other Study ID Numbers: COVERT

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No